Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 20/20 | 1.00 |
| ▸ | CCNK | O75909 | 11/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 11/20 | 0.79 |
| ▸ | CDK14 | O94921 | 2/20 | 0.79 |
| ▸ | CDK1 | P06493 | 2/20 | 0.79 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.79 |
| ▸ | CDK2 | P24941 | 2/20 | 0.79 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.79 |
| ▸ | CDK16 | Q00536 | 2/20 | 0.79 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.79 |
| ▸ | CDK7 | P50613 | 1/20 | 0.79 |
| ▸ | CCNH | P51946 | 1/20 | 0.79 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.79 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.79 |
| ▸ | CCNY | Q8ND76 | 1/20 | 0.79 |
| ▸ | CDK17 | Q00537 | 1/20 | 0.76 |
| ▸ | CDK18 | Q07002 | 1/20 | 0.76 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tambiciclib SCHEMBL31260227 | 1.00 | CDK9 (1.00) | CDK9CCNKCCNT1CDK14CDK1 | |
| Tambiciclib SCHEMBL21747508 | 1.00 | CDK9 (1.00) | CDK9CCNKCCNT1CDK14CDK1 | |
| Tambiciclib SCHEMBL28411949 | 1.00 | CDK9 (1.00) | CDK9CCNKCCNT1CDK14CDK1 | |
| Tambiciclib SCHEMBL31260243 | 1.00 | CDK9 (1.00) | CDK9CCNKCCNT1CDK14CDK1 | |
| Tambiciclib SCHEMBL23125451 | 1.00 | CDK9 (1.00) | CDK9CCNKCCNT1CDK14CDK1 | |
| Tambiciclib SCHEMBL23125424 | 1.00 | CDK9 (1.00) | CDK9CCNKCCNT1CDK14CDK1 | |
| SCHEMBL30151215 | 0.88 | CCNK (1.00) | CDK9CCNKCCNT1CDK14CDK1 | |
| SCHEMBL21747576 | 0.88 | CCNK (1.00) | CDK9CCNKCCNT1CDK14CDK1 | |
| SCHEMBL21747575 | 0.88 | CCNK (1.00) | CDK9CCNKCCNT1CDK14CDK1 | |
| SCHEMBL15377322 | 0.88 | CCNT1 (0.85) | CDK9CCNKCCNT1CDK14CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3613737-B1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2021-12-29 | — | — | EP | claimed |
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2021-03-23 | — | — | US | claimed |
| CN-108727363-B | Novel cyclin dependent kinase CDK9 inhibitor | 劲方医药科技(上海)有限公司 | 2020-06-19 | — | — | CN | claimed |
| US-20200078343-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | Shanghai Jiongshuo Pharmaceutical Technology Co., Ltd. (CN) | 2020-03-12 | — | — | US | claimed |
| EP-3613737-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2020-02-26 | — | — | EP | claimed |
| EP-3613737-B1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2021-12-29 | — | — | EP | disclosed |
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2021-03-23 | — | — | US | disclosed |
| CN-108727363-B | Novel cyclin dependent kinase CDK9 inhibitor | 劲方医药科技(上海)有限公司 | 2020-06-19 | — | — | CN | disclosed |
| US-20200078343-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | Shanghai Jiongshuo Pharmaceutical Technology Co., Ltd. (CN) | 2020-03-12 | — | — | US | disclosed |
| EP-3613737-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2020-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | CDK9, CDK19, CDK1 | CDK9 1/4885CCNK 14/4885CCNT1 32/4885 |
| US-20200078343-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | CDK9, CDK19, CDKL1 | CDK9 1/4885CCNK 17/4885CCNT1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.